Cargando…
Recent Development of Prodrugs of Gemcitabine
Gemcitabine is a nucleoside analog that has been used widely as an anticancer drug for the treatment of a variety of conditions, including ovarian, bladder, non-small-cell lung, pancreatic, and breast cancer. However, enzymatic deamination, fast systemic clearance, and the emergence of chemoresistan...
Autores principales: | Pandit, Bhoomika, Royzen, Maksim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954202/ https://www.ncbi.nlm.nih.gov/pubmed/35328020 http://dx.doi.org/10.3390/genes13030466 |
Ejemplares similares
-
Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years
por: Najjar, Anas, et al.
Publicado: (2020) -
Development and Bioorthogonal Activation of Palladium-Labile
Prodrugs of Gemcitabine
por: Weiss, Jason T., et al.
Publicado: (2014) -
Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine
por: Tsume, Yasuhiro, et al.
Publicado: (2017) -
Delivery of Gemcitabine Prodrugs Employing Mesoporous Silica Nanoparticles
por: Malfanti, Alessio, et al.
Publicado: (2016) -
Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy
por: Habib, Saffiya, et al.
Publicado: (2021)